vs

Side-by-side financial comparison of FIDELITY D & D BANCORP INC (FDBC) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $24.4M, roughly 1.5× FIDELITY D & D BANCORP INC). FIDELITY D & D BANCORP INC runs the higher net margin — 32.5% vs -3.7%, a 36.2% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 15.0%). FIDELITY D & D BANCORP INC produced more free cash flow last quarter ($24.8M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 11.8%).

Fidelity D & D Bancorp Inc is a US-based regional bank holding company primarily operating in northeastern Pennsylvania. It offers a full range of retail and commercial banking services including deposit accounts, consumer and business loans, mortgage lending, and wealth management solutions, catering to individual consumers, small businesses and local community clients.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

FDBC vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.5× larger
GYRE
$37.2M
$24.4M
FDBC
Growing faster (revenue YoY)
GYRE
GYRE
+18.5% gap
GYRE
33.4%
15.0%
FDBC
Higher net margin
FDBC
FDBC
36.2% more per $
FDBC
32.5%
-3.7%
GYRE
More free cash flow
FDBC
FDBC
$30.6M more FCF
FDBC
$24.8M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
11.8%
FDBC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDBC
FDBC
GYRE
GYRE
Revenue
$24.4M
$37.2M
Net Profit
$7.9M
$-1.4M
Gross Margin
95.3%
Operating Margin
37.7%
0.3%
Net Margin
32.5%
-3.7%
Revenue YoY
15.0%
33.4%
Net Profit YoY
36.1%
-340.1%
EPS (diluted)
$1.29
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDBC
FDBC
GYRE
GYRE
Q4 25
$24.4M
$37.2M
Q3 25
$23.5M
$30.6M
Q2 25
$23.3M
$26.8M
Q1 25
$22.0M
$22.1M
Q4 24
$21.2M
$27.9M
Q3 24
$20.4M
$25.5M
Q2 24
$19.7M
$25.2M
Q1 24
$19.5M
$27.2M
Net Profit
FDBC
FDBC
GYRE
GYRE
Q4 25
$7.9M
$-1.4M
Q3 25
$7.3M
$5.9M
Q2 25
$6.9M
$1.6M
Q1 25
$6.0M
$3.7M
Q4 24
$5.8M
$569.0K
Q3 24
$5.0M
$2.9M
Q2 24
$4.9M
$4.5M
Q1 24
$5.1M
$9.9M
Gross Margin
FDBC
FDBC
GYRE
GYRE
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
FDBC
FDBC
GYRE
GYRE
Q4 25
37.7%
0.3%
Q3 25
36.5%
22.7%
Q2 25
35.5%
8.1%
Q1 25
32.2%
10.3%
Q4 24
31.4%
2.4%
Q3 24
28.2%
16.6%
Q2 24
28.9%
12.7%
Q1 24
29.5%
29.7%
Net Margin
FDBC
FDBC
GYRE
GYRE
Q4 25
32.5%
-3.7%
Q3 25
31.2%
19.4%
Q2 25
29.7%
5.9%
Q1 25
27.2%
16.9%
Q4 24
27.5%
2.0%
Q3 24
24.3%
11.2%
Q2 24
25.0%
18.0%
Q1 24
25.9%
36.6%
EPS (diluted)
FDBC
FDBC
GYRE
GYRE
Q4 25
$1.29
$-0.01
Q3 25
$1.27
$0.03
Q2 25
$1.27
$0.00
Q1 25
$1.03
$0.00
Q4 24
$1.00
$0.00
Q3 24
$0.86
$0.01
Q2 24
$0.86
$0.01
Q1 24
$0.88
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDBC
FDBC
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$148.1M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$238.9M
$106.0M
Total Assets
$2.7B
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDBC
FDBC
GYRE
GYRE
Q4 25
$148.1M
$52.4M
Q3 25
$142.2M
$60.0M
Q2 25
$165.5M
$54.4M
Q1 25
$211.2M
$29.9M
Q4 24
$83.4M
$26.7M
Q3 24
$120.2M
$25.1M
Q2 24
$78.1M
$25.1M
Q1 24
$72.7M
$37.4M
Stockholders' Equity
FDBC
FDBC
GYRE
GYRE
Q4 25
$238.9M
$106.0M
Q3 25
$229.2M
$101.9M
Q2 25
$217.9M
$92.0M
Q1 25
$211.7M
$68.1M
Q4 24
$204.0M
$63.3M
Q3 24
$207.3M
$63.2M
Q2 24
$195.7M
$60.4M
Q1 24
$191.6M
$56.6M
Total Assets
FDBC
FDBC
GYRE
GYRE
Q4 25
$2.7B
$166.1M
Q3 25
$2.7B
$159.4M
Q2 25
$2.7B
$152.6M
Q1 25
$2.7B
$129.8M
Q4 24
$2.6B
$125.4M
Q3 24
$2.6B
$125.2M
Q2 24
$2.5B
$120.9M
Q1 24
$2.5B
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDBC
FDBC
GYRE
GYRE
Operating Cash FlowLast quarter
$42.4M
$-5.6M
Free Cash FlowOCF − Capex
$24.8M
$-5.8M
FCF MarginFCF / Revenue
101.7%
-15.5%
Capex IntensityCapex / Revenue
71.9%
0.4%
Cash ConversionOCF / Net Profit
5.34×
TTM Free Cash FlowTrailing 4 quarters
$45.4M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDBC
FDBC
GYRE
GYRE
Q4 25
$42.4M
$-5.6M
Q3 25
$8.4M
$4.7M
Q2 25
$12.6M
$2.1M
Q1 25
$11.7M
$-129.0K
Q4 24
$29.6M
$-2.8M
Q3 24
$9.1M
$1.7M
Q2 24
$8.7M
$-5.5M
Q1 24
$5.3M
$2.9M
Free Cash Flow
FDBC
FDBC
GYRE
GYRE
Q4 25
$24.8M
$-5.8M
Q3 25
$2.2M
$4.0M
Q2 25
$6.9M
$1.8M
Q1 25
$11.5M
$-251.0K
Q4 24
$24.9M
$-2.8M
Q3 24
$7.8M
$1.0M
Q2 24
$7.2M
$-6.9M
Q1 24
$4.0M
$2.7M
FCF Margin
FDBC
FDBC
GYRE
GYRE
Q4 25
101.7%
-15.5%
Q3 25
9.3%
13.1%
Q2 25
29.6%
6.8%
Q1 25
52.3%
-1.1%
Q4 24
117.3%
-10.1%
Q3 24
38.1%
4.1%
Q2 24
36.6%
-27.5%
Q1 24
20.7%
9.8%
Capex Intensity
FDBC
FDBC
GYRE
GYRE
Q4 25
71.9%
0.4%
Q3 25
26.5%
2.2%
Q2 25
24.4%
1.0%
Q1 25
0.8%
0.6%
Q4 24
22.0%
0.2%
Q3 24
6.3%
2.7%
Q2 24
7.5%
5.8%
Q1 24
6.7%
0.9%
Cash Conversion
FDBC
FDBC
GYRE
GYRE
Q4 25
5.34×
Q3 25
1.15×
0.79×
Q2 25
1.82×
1.32×
Q1 25
1.95×
-0.03×
Q4 24
5.07×
-4.85×
Q3 24
1.83×
0.60×
Q2 24
1.76×
-1.21×
Q1 24
1.05×
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons